Artelo Biosciences downgraded to Hold from Buy at D. Boral Capital

D. Boral Capital analyst Jason Kolbert downgraded Artelo Biosciences (ARTL) to Hold from Buy without a price target after the company announced a 6-for-1 reverse stock split set to take effect on June 13. The firm moved to the sidelines “as the company transitions through this corporate action.” The analyst sees limited near-term upside until the shares “find technical and investor support at a new base level.”